Patient satisfaction with laser therapy

Laser Therapy

Versatile treatment option for your patients

The value of laser therapy in BPH

Benign prostatic hyperplasia (BPH) is characterised by the development of lower urinary tract symptoms (LUTS), including voiding and storage problems, and has an increasing incidence in men over the age of 50 years.1,2 TURP is the current standard surgical procedure for men with prostate sizes of 30-80 mL and bothersome moderate-to-severe LUTS secondary of BPO.3 Alternative therapy methods are being considered, including laser therapy.3

Our laser therapy portfolio has the ability to deliver benefits to your patients in three key areas:

Technological advancements


Durable efficacy

Patient satisfaction

Compared to TURP, laser therapy has shown shorter hospitalisation and catheterisation times. Studies reporting median catheterisation times of 22 hours versus 46,7 hours and 90% success rate in same day catheter removal.5,6

At Boston Scientific, we continue to improve and develop our laser treatment portfolio. The GreenLight XPSTM Laser Therapy System has advanced technical specifications, with a maximum power of 180W and an improved beam geometry of the MoXyTM fiber.7

Lumenis PulseTM 120H Holmium Laser System with MOSESTM Technology provides 15% faster enucleation and 40% quicker hemostasis* than a standard holmium laser.8 The improvements in hemostasis can lead to better vision clarity and control, physicians can learn the HoLEP technique and build confidence after 20 procedures supervised by an experienced urologist.8-10

Learn more about the benefits of the MOSESTM Technology:

     *15% faster enucleation - (p=0.01) 40% quicker hemostasis - (p<0.001)

There are three types of laser technology you can choose from in the Boston Scientific BPH portfolio – photovaporization of the prostate (PVP) with GreenLight, holmium laser enucleation of the prostate (HoLEP) with Lumenis Pulse 120H Holmium Laser System with MOSES Technology, and Auriga XLTM 50W Holmium Laser.11,12

HoLEP and PVP are safe and effective alternatives to TURP.13 They have a proven track record of delivering lasting symptom relief with low retreatment rates at 5 and even 10 years.13,14

Explore key outcomes below:

Long-term improvements in symptoms with GreenLight XPSTM 13,15

Symptom relief and quality of life improvements vs baseline were maintained at 5 years.13,15

laser therapy


Another study with a five-year follow-up showed similarly results.15 This second study also showed 88% of patients were at least “mostly satisfied” with the treatment at the 5-year mark.15

A retrospective analysis found there were no long-term complications reported at 5 years13

There were a small number of long-term complications reported in another study:15

• One patient was prescribed anticholinergics

• Bladder neck contracture, urethral stricture, and reintervention for BPO were observed in two patients each

• Urinary incontinence was experienced by three patients

• Five patients were receiving alpha-blockers 


The Lumenis Pulse™ 120H Holmium Laser System delivers the long-term benefits of HoLEP.14

HoLEP with MOSES 2.0 laser, in comparison to standard, provides excellent and durable clinical outcomes (PVR, Qmax, IPSS, and QoL).14

laser therapy clinical data

*Compared to standard holmium.

**10-year follow-up reoperation rate as a result of recurrent obstruction from residual adenoma.


HoLEP demonstrates better outcomes than TURP with regards to hemoglobin loss, bladder irrigation, catheterization time, hospital stay, and blood transfusion.* MOSES™ 2.0 Technology is suited for a broad range of prostate sizes and patient types, including patients with large prostates and patients treated with anticoagulants, transforming the way BPH is manage 16, 17

*among patients with small to midsized prostates

88% (74/84) of patients were at least mostly satisfied 57 months after treatment with GreenLight XPS.5 to 15

92% (35/38) of patients were highly satisfied with the HoLEP procedure with a mean follow up of 6 years.16

Learn more about our laser portfolio

Decorative Image

Download the academic publications





1. Barry MJ, Roehrborn CG. Benign Prostatic Hyperplasia. BMJ. 2001;323:1042–1046.
2. Egan KB. The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract Symptoms: Prevalence and Incident Rates. Urol Clin North Am. 2016;43(3):289–297.
3. EAU Guidelines
4. Capitán C, Blázquez C, Martin MD, et al. GreenLight HPS 120-W Laser Vaporization Versus Transurethral Resection of the Prostate for the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Randomized Clinical Trial With 2-Year Follow-Up. Eur Urol. 2011;60(4):734–739.
5. Bachmann A, Tubaro A, Barber N, et al. 180-W XPS GreenLight Laser Vaporization Versus Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: 6-Month Safety and Efficacy Results of a European Multicentre Randomized Trial -The GOLIATH Study. Eur Urol. 2014;65(5):931–942.
6. Catheter Removal on the Same Day of Holmium Laser Enucleation of the Prostate: Outcomes of a Pilot Study by Deepak K. Agarwal, Marcelino E. Rivera, Charles U. Nottingham, Tim Large, and AmyE.Krambeck in Urology. 2020 Dec; 146: 225–229) 7. Data on File with Boston Scientific.
7: Data on file with Boston Scientific
8 Large T, Nottingham C, Stoughton C, et al. Comparative study of holmium laser enucleation of the prostate with MOSES enabled pulsed laser modulation. Urology. 2020;136:196–201.
9. Nevo A, Faraj KS, Cheney SM, et al. Holmium laser enucleation of the prostate using MOSES 2.0 vs non‐MOSES: a randomised controlled trial. BJU Int. 2021;127(5):553–559.
10. El‐Hakim A, Elhilali MM. Holmium laser enucleation of the prostate can be taught: the first learning experience. BJU Int. 2002;90(9):863–869.
11. GreenLight XPS Directions for Use.
12. Lumenis Pulse Directions for Use.
13. Ajib K, Mansour M, Zanaty M, et al. Photoselective vaporization of the prostate with the 180-W XPS Greenlightlaser: Five-year experience of safety, efficiency and functional outcomes. Can Urol Assoc J. 2018;12(7):E318–E324.
14. Elmansy HM, Kotb A, Elhilali MM. Holmium laser enucleation of the prostate: long-term durability of clinical outcomes and complication rates during 10 years of followup. J Urol. 2011;186(5):1972–1976.
15. Calves J, Thoulouzan M, Perrouin-Verbe MA, et al. Long-Term Patient-Reported Clinical Outcomes and Reoperation Rate After Photovaporization with the XPS-180W GreenLight Laser. Eur Urol Focus. 2019;5(4):676–680.
16. Gilling PJ, Aho TF, Frampton CM, et al. Holmium Laser Enucleation of the Prostate: Results at 6 Years. Eur Urol. 2008;53(4):744–749
17. Lerner LB, McVary KT, Barry MJ, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline 2021. J Urol. 2021;206:806
18. Agarwal DK, Rivera ME, Nottingham CU, et al. Catheter removal on the same day of holmium laser enucleation of the prostate: Outcomes of a pilot study. Urology. 2020;146:225‐9.